258 related articles for article (PubMed ID: 15003693)
1. Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro.
Tunney MM; Scott EM
J Microbiol Methods; 2004 Apr; 57(1):107-14. PubMed ID: 15003693
[TBL] [Abstract][Full Text] [Related]
2. Development of a rapid colorimetric time-kill assay for determining the in vitro activity of ceftazidime and tobramycin in combination against Pseudomonas aeruginosa.
Moriarty F; Elborn S; Tunney M
J Microbiol Methods; 2005 May; 61(2):171-9. PubMed ID: 15722142
[TBL] [Abstract][Full Text] [Related]
3. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
Treerat P; Widmer F; Middleton PG; Iredell J; George AM
FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
Traczewski MM; Brown SD
Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
[TBL] [Abstract][Full Text] [Related]
5. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
Moriarty TF; McElnay JC; Elborn JS; Tunney MM
Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria.
Peeters E; Nelis HJ; Coenye T
J Antimicrob Chemother; 2009 Oct; 64(4):801-9. PubMed ID: 19633000
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
Zhou J; Chen Y; Tabibi S; Alba L; Garber E; Saiman L
Antimicrob Agents Chemother; 2007 Mar; 51(3):1085-8. PubMed ID: 17158942
[TBL] [Abstract][Full Text] [Related]
8. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model.
Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647
[TBL] [Abstract][Full Text] [Related]
9. [Synergistic activity between ticarcillin, azlocillin, cefsulodin, ceftazidime and tobramycin or amikacin against Pseudomonas aeruginosa (author's transl)].
Petit JC; Richard G; Burghoffer B; Daguet GL
Pathol Biol (Paris); 1982 Jun; 30(6):426-31. PubMed ID: 6810286
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures.
Tré-Hardy M; Vanderbist F; Traore H; Devleeschouwer MJ
Int J Antimicrob Agents; 2008 Apr; 31(4):329-36. PubMed ID: 18280117
[TBL] [Abstract][Full Text] [Related]
11. Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.
Lapointe JR; Bourget C; Mainville S; Lafleur L; Lagacé J; Montplaisir S
J Chemother; 1989 Jul; 1(4 Suppl):184-6. PubMed ID: 16312360
[No Abstract] [Full Text] [Related]
12. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa.
Zuravleff JJ; Yu VL; Yee RB
J Lab Clin Med; 1983 Jun; 101(6):896-902. PubMed ID: 6406628
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of fosfomycin-gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa.
Pruekprasert P; Tunyapanit W
Southeast Asian J Trop Med Public Health; 2005 Sep; 36(5):1239-42. PubMed ID: 16438151
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
Mushtaq S; Warner M; Livermore DM
J Antimicrob Chemother; 2010 Nov; 65(11):2376-81. PubMed ID: 20801783
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
[TBL] [Abstract][Full Text] [Related]
16. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of S-(3,4-dichlorobenzyl)isothiourea hydrochloride and novel structurally related compounds against multidrug-resistant bacteria, including Pseudomonas aeruginosa and Burkholderia cepacia complex.
Nicholson A; Perry JD; James AL; Stanforth SP; Carnell S; Wilkinson K; Anjam Khan CM; De Soyza A; Gould FK
Int J Antimicrob Agents; 2012 Jan; 39(1):27-32. PubMed ID: 21993484
[TBL] [Abstract][Full Text] [Related]
18. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
Wu YL; Scott EM; Po AL; Tariq VN
APMIS; 1999 Jun; 107(6):585-92. PubMed ID: 10379686
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]